Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Battle of the bands: which hemorrhoid treatment wins?

NCT ID NCT07559630

Disease control Sponsor: Jessica K. Stewart, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study compares two standard treatments for bleeding internal hemorrhoids: hemorrhoidal artery embolization (HAE) and rubber band ligation (RBL). HAE uses a catheter to block blood flow to the hemorrhoid with tiny particles or coils, while RBL uses rubber bands to cut off circulation. The trial will enroll 40 adults with grade II-III internal hemorrhoids who have not improved with conservative care, and will track which treatment controls bleeding with fewer procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hemorrhoidal artery embolization (tiny particles or coils) and rubber band ligation
What this could lead to
If this trial succeeds, it could show which standard treatment is more effective for controlling hemorrhoidal bleeding and improving quality of life.
What could go wrong
This is a small, single-center trial with only 40 participants, so results may not apply to everyone. Both procedures have risks like pain, bleeding, or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Nov 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years and less than 90 years. 2. Ability to provide written informed consent. 3. Documented clinical history of chronic bleeding from internal hemorrhoids. 4. Documented presence of Goligher grade II-III internal hemorrhoids. 5. Failed conservative treatment for bleeding hemorrhoids (e.g. fiber supplementation, topical ointments and creams, dietary modifications, stool softeners, warm baths). 6. Able to comply with all treatments and protocol follow-up visits, in the opinion of the PI's. Exclusion Criteria: 1. Moderate loss of kidney function, defined as estimated glomerular filtration rate of less than 45 mL/min. 2. Significant arterial atherosclerosis that would limit selective angiography. 3. Known alternative causes of GI bleeding. 4. Allergy to iodinated contrast agents. 5. Active infection or malignancy. 6. Pregnancy. 7. Active nicotine use within the last 12 months. 8. Portal hypertension/rectal varices. 9. Uncorrectable coagulopathy (INR \> 2; Platelet count \<100,000; PTT \> 40 sec). 10. Findings on baseline CTA that adversely affect treatment, based on PI's clinical judgment, including but not limited to stenosis, occlusion, or hypoplasia of the superior and/or middle rectal arteries.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemorrhoid hereditary angioedema internal hemorrhoid retinoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAE Hemorrhoidal bleeding Hemorrhoids, internal RBL

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ronald Reagan UCLA Medical Center

    RECRUITING

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.